No Data
Arch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins
Arch Biopartners Closes Non-Brokered Private Placement
Arch Biopartners Arranges Non-Brokered Private Placement
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed With Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Says University Health Network Joining Phase II Trial of LSALT Peptide
